Successful Treatment of Full-Thickness Macular Hole in Polypoidal Choroidal Vasculopathy with Anti-VEGF Therapy.

• Type of Material: Article
• Authors: Aaron Lindeke-Myers, Emory University; Gregg T Kokame, University of Hawaii School of Medicine; Steven Yeh, Emory University; Jessica Shantha, Emory University
• Language: English
• Date: 2020-10-01
• Publisher: SAGE Publishing
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © The Author(s) 2020
• Final Published Version (URL): http://dx.doi.org/10.1177/2474126420909706
• Title of Journal or Parent Work: J Vitreoretin Dis
• Volume: 4
• Issue: 5
• Start Page: 433
• End Page: 436
• Grant/Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Building Interdisciplinary Careers in Women’s Health of the National Institutes of Health (K12HD085850 to J.S.); the M. Louise Simpson Endowment Fund (to S.Y.); an unrestricted grant from Research to Prevent Blindness to the Emory Eye Center and National Eye Institute, National Institutes of Health Core Grant to Emory University (P30EY006360); and the National Eye Institute of the National Institutes of Health (awards RO1 EY029594 and K23EY030158). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
• Keywords: full thickness macular hole (FTMH); bevacizumab; macular hole (MH); Polypoidal choroidal vasculopathy (PCV)
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

PURPOSE: To report a case of an 86-year-old man with a full thickness macular hole (FTMH) secondary to polypoidal choroidal vasculopathy (PCV) treated with bevacizumab. METHODS: A retrospective case report is presented. RESULTS: An 86-year-old male presented with a five-month history of metamorphopsia and decreased vision in his right eye and was found to have active exudation secondary to PCV with a concurrent FTMH. After four treatments with intravitreal bevacizumab, the FTMH resolved without surgical intervention. CONCLUSIONS: The patient's FTMH resolved with solely pharmacologic treatment as a result of treating his PCV with intravitreal bevacizumab. MH formation secondary to PCV is a rare finding, but may be successfully treated with pharmacologic therapy without surgical intervention.